Undeclared muscle relaxants and anti-inflammatory drugs could interact with a patient’s care.
Undeclared muscle relaxants and anti-inflammatory drugs could interact with a patient’s care.
Millions of workers are changing occupations, leading to ripple effects for comp.
Spending and utilization are returning to pre-pandemic levels, with biologics growing in prominence.
The public comment period is underway for this action, which could help with safer drug disposal.
Healthe’s VP of Clinical Services will join a discussion on post-COVID lessons for workers’ comp.
VX-548 delivered significant improvements in pain with few adverse events.
Women workers were more adversely impacted by the pandemic and the recession.
Quest Diagnostics reports increased positivity rates for marijuana in employee drug screenings.
Adults aged 50 and older and immunocompromised individuals may receive a second booster dose.
Carriers share their thoughts on successful RTW programs.
A new muscle relaxant for the treatment of spasticity, including from spinal cord injuries.
Nearly 500 stakeholders share their thoughts on industry challenges and priorities.
Proposed changes are open to public comment until April 11th.
After a drop in activity due to the pandemic, five states are now considering legislation.
Healthe’s VP of Industry and State Affairs, Sandy Shtab, joined an educational webinar from IAIABC.
Buprenorphine is an opioid used to treat pain, as well as opioid-use disorder.
Legislation could potentially reclassify gig workers as employees entitled to workers’ comp.
Drug advancements surrounding the prevention and treatment of COVID-19.
Since the start of 2022, at least 10 states are considering some form of marijuana legislation.
Healthe’s Director of Product Management talks to Risk & Insurance on how to attract and retain talent in the workers’ comp industry.
This autoimmune drug was approved for various arthritic and autoimmune diseases.
The initial results from a collaborative survey between Healthe and Risk & Insurance.®
Phase 3 trials for NVX-CoV2373 across 30,000 people found this vaccine candidate to be safe and effective for the prevention of COVID-19.
New five-day rules are recommended, with variation depending upon vaccination status.
The Bureau of Labor Statistics reports that 4.5 million employees quit their jobs in November 2021.
Healthe’s SVP of Product Strategy and Innovation, Kristine Kennedy, discusses this topic with Risk & Insurance magazine.
Molnupiravir, Paxlovid, and AZD7442 have shown promise in Phase 3 trials.
Those previously infected by the virus may face long-term health complications.
A new study found that VR sessions averaged a 40% reduction in pain and decreased opioid use.
Rulings from U.S. District Courts have impeded vaccine requirements among certain workers.
All adults may now receive a booster shot of any COVID-19 vaccine.
Strategies for a safer, healthier workforce amid COVID-19 and beyond.
All COVID-19 vaccines now have emergency use authorization for a booster dose.
One-third of employees have witnessed cannabis use during work hours.
Pre-pandemic, 951 claims received telemedicine, jumping to 21,000 during the pandemic.
Visit Healthe at WCI booth #913! Plus, a recap of a SAWCA roundtable, featuring Sandy Shtab.
A new migraine medication, various generics, and more.
Long-term health impacts of COVID-19 can complicate claims
A WCRI study found that in some states 17% of workers receive topical analgesics.
Take our survey and share your thoughts on where the industry is headed.
Take part in our virtual speaking sessions at PRIMA and Comp Laude!
The Pfizer vaccine receives full FDA approval, while a new EUA authorizes booster shots for certain populations.
Healthe’s Director of Enterprise Analytics discusses in WorkCompWire how natural language processing can assist with claim review, population management, and more.
Less than 1% of gabapentin prescriptions were prescribed for an FDA-approved diagnosis.
All federal employees are impacted, as are companies with 100 or more employees.
Join our educational session on infectious disease safety in the workplace, and don’t miss a chance to take part in our industry survey!
The FDA approved first-time generics for Xeljanz, two COPD medications, and more.
Healthe’s Director of Product Management explains how centralized data helps claims professionals.
A new WCRI report explores the impact recent opioid legislation has had on injured worker care.
Another WCRI report looks at non-COVID-19 claims with injuries in the first two quarters of 2019 and 2020.
Not enough time for white papers or industry reports? Check out our Clinical Minute videos!
A joint statement announces that at this time, vaccinated adults are protected from the Delta variant.
Extensive isolation and unique stressors may impact the mental health of remote workers.
Changes center around improving the assessment of mental and behavioral impairment.
Connecticut legalizes recreational use, and NCCI expects even more states to follow suit.
Join our VP of Clinical Services on July 29th for a discussion on care and program considerations for underrepresented populations.
Wegovy (semaglutide) and sotrovimab will soon be available.
How to leverage the patient’s influence over care outcomes.
A new flash report from the WCRI highlights trends in drug utilization.
Corrections officers in Nebraska benefit from a new law; will healthcare workers in Connecticut join them?
Check out Healthe’s latest featured article with WorkCompWire
Join our VP of Clinical Services on July 15th for a discussion on underrepresented populations in workers' comp.
A new 8 mg naloxone nasal spray will soon be available, which is the largest naloxone dose approved by the FDA to date.
The latest issue of Healthesystems’ biannual clinical journal covers trending and influential topics in workers’ comp.
Our VP of Clinical Services comments on opioid alternatives, and our AVP of Advocacy & Compliance discusses social media in the workplace.
Due to mutating viral strains, the potential benefits of this COVID-19 drug no longer outweigh the risks.
While many states are making decisions regarding gig workers, federal action could soon change things.
After reviewing six rare cases of blood clots after 7 million doses, current data indicates the vaccine is safe.
More states consider allowing injured workers to choose their treating physician.
In two months, three states legalized recreational marijuana, and more could soon follow.
Join Healthe’s Heather Stempien and Sandy Shtab for a panel presentation with IAIABC on April 28th!
A new 500mg injection will soon be available.
Over 600 stakeholders shared their thoughts on top industry challenges.
Among 1,600 emergency department workers, 46% had burnout symptoms.
Both State Supreme Courts ruled in favor of reimbursement.
The single-dose Janssen vaccine was analyzed in a trial of 39,000 patients.
A novel bupivacaine formulation works as a 72-hour local anesthetic following shoulder surgery.
Healthe leaders share their thoughts with Risk & Insurance®
New data from a safety trial creates concern surrounding the rheumatoid arthritis drug.
State-led efforts to combat the drug price issue continue to emerge across the nation.
Healthe’s AVP of Advocacy & Compliance will provide guidance on workers’ comp regulations.
Join us for a panel discussion on March 10th as part of the NWCDC Digital Session Series.
False negatives may be reported due to genetic variations of the virus.
Kristine Kennedy, SVP of Product Strategy and Innovation, talks to Risk & Insurance®
A new report from IQVIA found that national MME dropped 17% from 2019 to 2020.
The Department of Labor issued a new rule while special interest groups push for regulatory change.
Alleged violations of the Controlled Substances Act could result in billions of dollars in penalties.
Initial insights from Healthesystems’ annual industry survey.
Vaccine candidates from Pfizer-BioNTech and Moderna received EUAs, as did the first at-home test that delivers results in 30 minutes, and two treatments for the virus.
Navigating the workers’ comp process can be daunting for patients, and empathy can go a long way in improving outcomes.
A new report explores how COVID-19 has impacted telemedicine, as well as opportunities for expansion.
Stakeholders will soon experience a streamlined digital process for managing claims.
Healthesystems’ Chief Medical Officer comments on the U.S. House’s approval of marijuana decriminalization.
Veklury is approved for hospitalized patients, while bamlanivimab is being investigated in mild-to-moderate cases of COVID-19.
Across the nation, not only is marijuana growing more accepted, but so are other drugs like psilocybin and MDMA.
Direct customer exposure is associated with a five-fold risk of infection, while less social distancing in the workplace is tied to depression and anxiety.
The election saw passage of a measure to exempt rideshare drivers from employee status, impacting benefits and more.
Join our VP of Clinical Services, Silvia Sacalis, for a digital presentation on employing empathy within workers’ comp programs on December 9th!
Even at recommended doses, benzodiazepine use can lead to misuse, abuse, and addiction.
User research indicates that patients face difficulty with the intake process, getting key claim information, and more.
The drug manufacturer is pleading guilty and paying out billions.
COVID-19 claim data through October 5th has been captured and broken down by industry, age, region, and more.
Learn how our pharmacists make a difference for injured worker patients, and what drives their hard work
Olinvyk injections and Qdolo oral solution are approved for the management of acute pain.
With the pandemic disrupting the healthcare system, how has workers’ comp been impacted?
Data from 26,000 claims finds that early physical therapy reduces costs and disability duration.
A wide-sweeping order on national telehealth policy requires federal agencies to begin making plans for change.
Data from nearly 12,000 COVID-19 claims breaks down coverage among industries, telemedicine insights, and more.
2020 has been a year of disruption, and we want to know what the industry thinks about COVID-19, telehealth, opioids, AI, and more!
The FDA recommends healthcare professionals co-prescribe the opioid overdose reversal drug with all opioid prescriptions.
Healthesystems’ VP of Clinical Services addresses COVID-19 disruptions to workers’ comp, along with helpful strategies
AMA hopes to shift from a crisis-reaction framework to a more holistic model that prevents overdose while helping pain patients receive care.
Beyond first responders and healthcare workers, essential workers including grocery store workers are now covered by workers’ comp.
With cases increasing as individuals return to work, injured workers face barriers to care, risk of infection, and more.
As complex claims continue to impact workers’ comp, our new article in WorkCompWire addresses the need for early warnings and clinical guidance.
Subcutaneous injections of the new biologic, adalimumab-fkjp, were approved for seven indications.
Strategies for anticipating and mitigating complex claim risks.
The AMA suggests that prescription medications are no longer a significant factor in the opioid epidemic, and that opioid prescription limits should change.
Arkansas and Louisiana enacted policies to protect businesses from civil liability stemming from COVID-19 exposure.
Data from 28 states years found that NSAIDs and dermatological agents are seeing growth in spending.
The malaria drug loses an EUA for COVID-19, while the FDA warns of drug interactions that can reduce antiviral effectiveness.
With opioid utilization decreasing, what concerns do other pain therapies pose?
With data from 36 states across 12 years, this report highlights the differences in prices paid for medical services across the nation.
Occupations are divided into risk categories where each category must utilize appropriate face coverings, masks, or respirators.
The National Safety Council discusses managing employee anxiety stemming from COVID-19 when returning to work.
Elyxyb (celecoxib) is an NSAID for the acute treatment of migraine with or without aura.
How comorbidities, fatigue, and mental health impact claims management.
The FDA allows emergency use in response to positive trials, but more research is needed.
A new study explores patients’ use of health services, the impact on medicine use, research activity, and more.
Many states expanded workers’ comp for COVID-19, but California casts a wider net.
New developments with diagnostic testing and the use of chloroquine and hydroxychloroquine.
Healthesystems’ AVP of Advocacy & Compliance discusses regulatory action related to COVID-19 with WorkCompWire.
The FDA, JAMA, and others think blood from those who recovered from COVID-19 could benefit those with the illness.
With frontline workers at risk, states are expanding coverage to healthcare workers, first responders, and other frontline workers.
Healthesystems’ VP of Clinical Services discusses population trends, non-opioid pain therapies, and comorbidities with WorkCompWire.
Healthesystems has created a developments webpage to track updates impacting workers’ comp.
Anjeso and a new Advil formulation target pain, while Nurtec™ and Vyepti™ target migraines.
Healthesystems collaborated with Risk & Insurance to survey 669 workers’ comp professionals on top trends and challenges.
A study of 41,000 adults finds that only treatment with buprenorphine or methadone reduced risk of overdose.
Several state workers’ comp programs are relaxing telehealth rules to promote social distancing.
Healthesystems’ AVP of Advocacy & Compliance discusses industry challenges, special initiatives, and more in a video spotlight.
A new seizure drug has been approved, and a nerve growth drug advances in clinical trials.
What will 2020 hold for marijuana acceptance, employee misclassification, formularies, and AI?
An analysis of 1.5 million claims found early physical therapy lowers odds of opioid use by 14%.
Testing positive for marijuana use could one day no longer prohibit employment.
With a flurry of opioid developments lately, what does the big picture look like?
Migraine, arthritis, and insomnia drug approvals, and a gabapentinoids safety warning.
Does the active ingredient in magic mushrooms have a future in mental health?
Phase 3 studies are underway, and current research sees potential for MDMA in psychotherapy.
A recent meta-analysis of over 100 trials and studies found lavender to significantly reduce anxiety levels.
With CBD products widely available and advertised for so many ailments, claimants could be using CBD without insurers knowing.
A biosimilar to Humira is approved, the FDA Fast Tracks a PTSD drug, and more.
Understand how prices are set for medical equipment and services, and how to scrutinize those costs.
According to the CWCI, reduced opioid utilization from 2010-2017 saved $6.5 billion in California comp costs.
Beyond compensability, Minnesota considers rules for evaluation, treatment planning, acceptable psychotherapies, and more.
Workers’ comp publications cover Healthesystems content surrounding aging physicians, successful return-to-work programs, and more.
A previous gastrointestinal drug recall expands, while a new recall for an anxiety drug is issued.
How more dynamic data can illuminate program performance to empower care delivery
The guideline covers a wide range of relevant topics, including pain, dosing, dangerous co-prescribing, comorbidities, and more.
Shortly after California made strides on employee classification for gig economy jobs, New Jersey and New York have taken action.
The Society of Actuaries published a report that claims the economic burden of the opioid epidemic was $631 billion from 2015-2018.
Indicated for various gastrointestinal concerns, these recalls could impact certain workers’ comp patients.
A new white paper explores clinical, legislative, workplace safety, and PBM considerations surrounding marijuana.
PwC explores how social factors impact chronic health conditions.
This reclassification will entitle millions of workers to benefits previously withheld, including workers’ comp.
Join Healthesystems at booth #1922, at an educational presentation, or by taking our industry survey with Risk & Insurance.
NKTR-181 (loxicodegol) was to receive an approval decision by August 29th, but a reevaluation of opioid policy has resulted in a delay.
Healthesystems’ clinical leaders speak to mitigation strategies to reduce workplace injuries stemming from fatigue.
The utilization of opioids, compounds, and physician-dispensed medications have significantly decreased.
Proposed changes to who can grow and research marijuana will soon be available for public commentary.
An Oklahoma judge found the drug maker to be partially responsible for the harm of the opioid epidemic.
Healthesystems’ Chief Medical Officer explores trends impacting workers’ comp, including patient engagement, population health, and more.
Nine generic versions of Lyrica (pregabalin) have been approved for the treatment of five different medical conditions.
Sandy Shtab has been recognized for making significant contributions to the workers’ comp industry.
Looking at over 29 billion private health claims, this study found that claim lines related to telehealth rose 624% from 2014-2018.
While many states report fewer opioid prescriptions, MME levels vary more significantly by state.
NCCI estimates that a 25-75% reduction in motor vehicle accidents in workers’ comp could save $1-4 billion, creating interest in self-driving cars.
Generic versions of Ultram (tramadol hydrochloride) tablets and Dyloject (diclofenac sodium) injections have been approved by the FDA.
While the utilization of opioids and other problematic drugs decreased, similar drops were seen in states without closed formularies.
Stephanie Arkelian has been recognized as a talented young professional making a positive impact on the workers’ comp industry.
Beyond exceptions for safety or federal positions, employers cannot refuse employment for testing positive for marijuana in pre-employment drug screenings.
A new study builds upon earlier research with a larger, more up-to-date dataset, finding a reversal in trends.
Visit Healthesystems in booth #909 and learn how we’re making waves in workers’ comp, and how we hope to benefit coastal cleanups for the “Coast to Coast” theme.
Orphengesic Forte has received a decision date of August 14, 2019.
How services like Lyft and Uber can amplify injured worker transportation programs to improve claims outcomes.
Though they’re only needed for special cases in workers’ comp, anticancer medications can easily exceed $10,000 per monthly fill.
Though most forms of marijuana are highly regulated, CBD products are readily available across the country. What does this mean for healthcare?
In a call for public comment, the FDA believes that reducing excess opioid supplies can lower opioid misuse, abuse, and overdose.
The life saving antidote for opioid overdose will soon be available in a consumer-friendly, generic nasal spray.
Healthesystems partnered with Risk & Insurance magazine to survey 500+ work comp professionals on their top challenges, trends, successes, and more.
Combining all three drugs can reduce claim closure rates to 58.3%, with average claim costs of $94,000.
Florida enacted a law to cover 21 different cancers, while other states like Montana, Maryland, and Virginia have recently passed similar laws.
Four research sites will test proven opioid prevention and treatment interventions, hoping to reduce overdose deaths by 40% over three years.
New changes to REMS safety programs will require stronger treatment documentation and oversight.
Patient engagement can lead to better health outcomes, but not all engagement strategies are equally effective.
The workforce is aging, getting younger, and gaining more women, all at once. What does that mean for claims management?
Congress may soon clear federal restrictions to processing marijuana transactions, while the FDA asks for feedback on handling marijuana products.
Various state and local governments have sued drug developers for the harms of the opioid epidemic, and this could be the first of many settlements.
Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.
Demographic factors such as gender, ethnicity, socioeconomic status, age, and location can impact opioid risks.
Despite having little clinical impact, topical creams continue to be utilized widely in workers’ comp.
Federal lawmakers and administrative agencies continue to investigate how to best lower ever-increasing drug prices.
Can special implants in the brain override paralysis? The FDA believes one day they could.
The FDA created special drug labels to clear a development hurdle and encourage manufacturers.
Dr. Robert Goldberg and Sandy Shtab talk with Risk & Insurance about changing attitudes and policies around medical marijuana, its potential role in reducing reliance on opioids, and what this can mean for payers, employers, patients and PBMs.
Prescribing has doubled since 2003, overdose deaths quadrupled since 1996, and misuse accounts for 20% of benzodiazepine use.
Kentucky, Connecticut, Idaho, and West Virginia proposed bills to make PTSD compensable for first responders.
A new JAMA study finds that increased county-level opioid marketing was tied to elevated overdose mortality.
The opioid prodrug for acute pain will soon be available in both a stronger and weaker dose.
As 2018’s legislative trends continue to spill into 2019, what big initiatives might impact workers’ comp this year?
An analysis of 90,000 private claims explores the relationship between early PT and reduced long-term opioid use in musculoskeletal pain.
Can doctors in certain states refer patients to pharmacies which they partially own?
Will doctors one day prescribe apps meant to drive behavior changes instead of drugs?
The reSET-O app uses cognitive behavioral therapy techniques to assist patients engaged in medication-assisted therapy for opioid dependence.
Formulary and claims management considerations for populations at risk for “mental-only” cases of PTSD.
The American Gastroenterological Association released guidance on properly prescribing medications for OIC.
Marijuana use among adults aged 50-64 tripled from 2002-2014.
Dr. Silvia Sacalis of Healthesystems teamed up with Dr. Adam Seidner of The Hartford for a session at NWCDC – here are 5 key takeaways.
Five-to-ten times stronger than fentanyl, this drug is not for consumer use, and many claim it could worsen the opioid crisis.
Healthesystems’ clinical leaders comment on the collective responsibility of healthcare entities, providers, and legislators to increase efforts that will help stem opioid overprescribing, misuse and overdose.
More states allow for the legalization of recreational and medical marijuana, while others consider insurance reimbursement.
A study of 9,596 claimants who filled an opioid prescription found that 30% were still taking opioids 90 days later.
Join our VP of Clinical Services on December 6th in Las Vegas for a presentation on value-based care in workers’ comp.
The marijuana-derived seizure drug now sits at schedule V, facing far fewer prescribing and dispensing restrictions.
Healthesystems’ VP of Clinical Services offers insight into prescriptions in workers’ comp claims that should raise concerns.
Assembly No. 4505 may solidify precedence recently made by a judge from the Division of Workers’ Compensation.
Common risk factors can increase worker fatigue, leading to more frequent workplace injuries and a loss of productivity.
With an enormous range of initiatives to prevent and treat opioid use disorder, the bill has officially been signed by the President.
Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.
Healthesystems’ VP of Clinical Services explains how too many drugs in a claim can cause health concerns, and what can be done to prevent them.
The FDA is working to create new opioid prescribing practices and guidelines, while also shifting drug development priorities for pain medications.
According to 2016-2017 data, over 20% of polypharmacy claims are over 10 years old, with more than 50% of them for patients aged 50 and older.
On average, construction workers are six times more likely to die from an opioid overdose death, more than any other occupation.
Healthesystems’ Chief Medical Officer spoke with WorkCompCentral regarding DEA plans to reduce opioid manufacturing.
NKTR-181 is supposed to offer a lower frequency of opioid side effects. But are more opioids really the solution we need to the opioid crisis?
Healthesystems’ AVP of Advocacy & Compliance explains how regulation has been unable to keep pace with healthcare innovation & technology.
More states cover PTSD without physical injuries for first responders, and 24 states allow PTSD patients to use medical marijuana.
A new wave of drugs that suppress CGRP proteins to reduce migraines could be on the horizon.
Drugs to treat opioid dependence could be approved under new clinical endpoints other than reducing opioid use.
Our Chief Medical Officer and VP of Clinical Services comment on matters such as the use of anticonvulsants to treat pain and opioid prescriptions for inpatients.
Phase 2/3 clinical trial results for Korsuva demonstrate pain relief with fewer side effects.
Millennials are more diverse and more open to alternative therapies, medical marijuana, healthcare technology, and dialogue surrounding psychosocial concerns.
A flurry of recent developments continues to bring the medical marijuana debate front and center, including further legalization, a Senate bill, a drug approval, and more.
In a randomized clinical trial of 460 patients, researchers found the treatment to have similar impact on self-rated disability as standard wound dressing.
Visit Healthesystems in booth #914 to see how we explore the conference’s “Cosmic” theme, and for a chance to win a $250 gift card.
The FDA recently approved drugs to treat opioid dependence, migraines, and rheumatoid arthritis.
Among many findings, JAMA reports that 20% of deaths among those aged 25-34 were opioid-related.
Within the last month, laws have passed in Tennessee, Colorado, South Carolina, Oklahoma, and Hawaii.
Global spending on cancer therapies now exceeds $133 billion.
Our Chief Medical Officer and VP of Clinical Services comment on the clinical use of ecstasy and marijuana.
A newly released draft guidance encourages the development of more sustained-release buprenorphine products.
In-depth reports for 16 different states examine medical payments, costs, duration of disability, and more.
Senate Bill 336 passed with a 44-6 vote and is now headed to the House.
Kratom continues to grow in popularity as a drug for pain and opioid withdrawal, despite concerns from the FDA, CDC and DEA.
In a special partner post with WorkCompWire, Healthesystems discusses developments in pain management, specialty drugs, and more.
If approved, Lucemyra (lofexidine) would be the first non-opioid drug approved to treat the symptoms of opioid withdrawal.
Healthesystems’ VP of Clinical Services discusses how workers’ comp is embracing a value-driven approach.
A new study analyzes the characteristics of chronic opioid use claims, while also examining opioid weaning data.
A Florida bill was recently signed into law, and states such as Arizona, Utah, Connecticut, and Oregon may follow suit.
Indiana and Kentucky signed off on formulary bills, while other states continue to make progress on their promised formularies.
Healthesystems’ Chief Medical Officer will present "Can Workers’ Comp Catch Up to the Rest of Healthcare?" at the 2018 IRSG Annual Conference.
Apadaz oral tablets were approved for the short-term management of acute pain, at no more than 14 days of use.
Healthesystems' VP of Clinical Services will co-present Workers' Comp Opioid Use Trends and Effective Population Health Management
The number of opioid-dependent injured workers in the Ohio workers' comp system fell 19% in 2017.
Many states have attempted to implement fee schedules for air ambulances, but courts citing federal regulations have stricken them down.
Forty-one states and over 200 cities and counties claim drug makers deceived patients and doctors regarding opioid safety and addiction risks.
Senna Laxative bottles were found to contain NSAIDs, while 55 lots of compounded drugs face questionable sterility.
A visual depiction of how opioid side effects can cascade across the body.
When taken in excessive doses, the anti-diarrhea drug loperamide can mimic opioid euphoria, and toxicity events and deaths are on the rise.
The passage of opioid action plans in Arizona, Tennessee, and Pennsylvania are the most recent additions to growing statewide efforts to curb the epidemic.
In 2003, gig workers made up less than 5% of the workforce. Today, estimates vary between 8% and 40%, raising questions for comp.
FDA, opioid, opioids, opioid policy, opioid policies, drug development, non-opioid
Machine learning aims to automate parts of claims management.
Despite decreases in prescribing rates, the opioid epidemic claims more lives than ever before, partially due to synthetic formulations.
The Department of Justice’s recent announcement may come to a head with the will of state governments and popular opinion.
By 2020, millennials will make up half the workforce, so how will they impact workers’ comp?
